This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by van Zon, A. Articles by Wiemer, E. A. C. Search for Related Content PubMed PubMed Citation Articles by van Zon, A. Articles by Wiemer, E. A. C.

Efflux Kinetics and Intracellular Distribution of Daunorubicin Are Not Affected by Major Vault Protein/Lung Resistance-Related Protein (Vault) Expression

¹ Department of Hematology, Erasmus Medical Center, Rotterdam, The Netherlands; ² Department of Pathology, Free University Medical Center, Amsterdam, The Netherlands; and ³ Department of Medical Oncology, Erasmus Medical Center/Josephine Nefkens Institute, Rotterdam, The Netherlands

Vaults may contribute to multidrug resistance by transporting drugs away from their subcellular targets. To study the involvement of vaults in the extrusion of anthracyclines from the nucleus, we investigated the handling of daunorubicin by drug-sensitive and drug-resistant non-small lung cancer cells, including a green fluorescent protein (GFP)-tagged major vault protein (MVP)-overexpressing transfectant (SW1573/MVP-GFP). Cells were exposed to 1 µM daunorubicin for 60 min, after which the cells were allowed to efflux the accumulated drug. No significant differences in daunorubicin efflux kinetics were observed between the sensitive SW1573 and SW1573/MVP-GFP transfectant, whereas the drug-resistant SW1573/2R120 cells clearly demonstrated an increased efflux rate. It was noted that the redistribution of daunorubicin from the nucleus into distinct vesicular structures in the cytoplasm was not accompanied by changes in the intracellular localization of vaults. Similar experiments were performed using mouse embryonic fibroblasts derived from wild-type and MVP knockout mice, which were previously shown to be devoid of vault particles. Both cell lines showed comparable drug efflux rates, and the intracellular distribution of daunorubicin in time was identical. Reintroduction of a human MVP tagged with GFP in the MVP^–/– cells results in the formation of vault particles but did not give rise an altered daunorubicin handling compared with MVP^–/– cells expressing GFP. Our results indicate that vaults are not directly involved in the sequestration of anthracyclines in vesicles nor in their efflux from the nucleus.

This article has been cited by other articles:

				M. Herlevsen, G. Oxford, C. R. Owens, M. Conaway, and D. Theodorescu Depletion of major vault protein increases doxorubicin sensitivity and nuclear accumulation and disrupts its sequestration in lysosomes Mol. Cancer Ther., June 1, 2007; 6(6): 1804 - 1813. [Abstract] [Full Text] [PDF]

				S. Raval-Fernandes, V. A. Kickhoefer, C. Kitchen, and L. H. Rome Increased Susceptibility of Vault Poly(ADP-Ribose) Polymerase-Deficient Mice to Carcinogen-Induced Tumorigenesis Cancer Res., October 1, 2005; 65(19): 8846 - 8852. [Abstract] [Full Text] [PDF]

				C. Yi, S. Li, X. Chen, E. A.C. Wiemer, J. Wang, N. Wei, and X. W. Deng Major Vault Protein, in Concert with Constitutively Photomorphogenic 1, Negatively Regulates c-Jun-Mediated Activator Protein 1 Transcription in Mammalian Cells Cancer Res., July 1, 2005; 65(13): 5835 - 5840. [Abstract] [Full Text] [PDF]